All In MedTech

Device Trial Radar · NCT06470035

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)

A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Major Depressive Disorder (MDD) - Modius Mood Study

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 6, 2027

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Neurovalens Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jun 24, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Major Depressive Disorder (MDD) - Modius Mood Study The aim of this study: To better evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS) as a method of treating major depressive disorder(MDD) , as compared to a sham control. Allocation: Randomized to either active device or control device usage. Endpoint classification: Efficacy Study Intervention Model: Parallel Assignment in 1:1 active to control allocation

Conditions

  • Major Depressive Disorder \(MDD
  • Depressive Disorder, Major

Interventions

  • Active VeNS DeviceDevice

    Battery powered non-invasive neurostimulation device

  • Sham VeNS DeviceDevice

    Placebo comparator sham device (no active stimulation)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hamilton Depression Rating Scale (HDRS-17)Time frame: Change in score from baseline to 6 weeks
  2. Hamilton Depression Rating Scale (HDRS-17)Time frame: 6 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • VA San Diego Healthcare System

    San Diego, California

  • Biomedical Science Research University of Ulster, Coleraine

    Belfast, Co.Antrim, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.